Skip to main content

Table 2 Associations of the single-nucleotide polymorphisms rs2231142 in ABCG2 with comorbidities of the gout patients

From: ABCG2 gene polymorphism rs2231142 is associated with gout comorbidities but not allopurinol response in primary gout patients of a Chinese Han male population

Comorbidities (with/without)   (1) GG (2) TG (3) TT (1)vs.(2)vs.(3) F/x2, P value (1)vs.(2) F/x2, P value (1)vs.(2)
OR
(95% CI)
(1)vs.(3) F/x2, P value (1)vs.(3)
OR
(95%CI)
(2)vs.(3) F/x2, P value (2)vs.(3)
OR
(95%CI)
Hypertention W/Oa 198/110 340/226 175/120 1.952,0.377 1.19 1.08 0.91
(n = 713) %b 64.3 60.1 59.3    (0.91–1.44)   (0.79–1.48)   (0.69–1.20)
Diabetes W/O 48/270 109/471 54/241 2.033,0.362 0.95 1.23 1.29
(n = 211) %b 15.1 18.8 18.3    (0.60–1.51)   (0.70–2.15)   (0.79–2.12)
Hyperlipidaemia W/O 215/106 387/202 206/95 0.684,0.711 1.17 1.39 1.2
(n = 808) %b 67.0 65.7 68.4    (0.87–1.59)   (0.91–1.99)   (0.86–1.63)
Obesity W/O 234/63 411/140 209/73 2.276,0.320 1.44 1.75 1.21
(n = 854) %b 78.8 74.6 74.1    (1.09–1.90)   (1.26–2.43)   (0.90–1.64)
Tophi W/O 62/214 116/414 68/202 1.137,0.566 1.02 0.84 0.83
(n = 246) %b 22.5 21.9 25.2    (0.71–1.44)   (0.57–1.25)   (0.59–1.17)
Nephrolithiasis W/O 62/231 109/450 39/267 8.495,0.014 0.331,0.565 0.78 7.561,0.006 0.54 6.361,0.012 0.60
(n = 210) %b 21.2 19.5 12.7    (0.55–1.12)   (0.35–0.84)   (0.41–0.90)
CKD W/O 159/145 306/251 179/106 7.291,0.026 0.550,0.459 0.90 6.637,0.010 1.54 4.781,0.029 1.39
(n = 854) %b 52.3 54.9 62.8    (0.68–1.19)   (1.11–2.14)   (1.03–1.86)
CKD
stage = 1
(n = 540)
  134 259 147 52.478,< 0.001       
%c 44.1 46.5 51.6        
CKD
stage≥2
(n = 104)
  25 47 32 7.288,0.026       
%c 8.2 8.4 11.2        
CKD
stage≥3
(n = 13)
  2 4 7 2.923,0.232       
%c 0.6 0.7 2.5        
  1. CI confidence interval, OR odds ratio
  2. a The number of the patients of the same genotype with/without the comorbidity (Patients with uncertain status of the comorbidity were excluded)
  3. b The frequency of the comorbidity in the patients with the same genotype (Patients with uncertain status of the comorbidity were excluded)
  4. c The frequency of CKD at a certain stage in the patients with the same genotype (Patients with uncertain status of CKD were excluded)